

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Neutropenic Sepsis

First Guidance Development Group (GDG) meeting

Tuesday 21st – Wednesday 22nd September 2010

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Prof Barry Hancock (BH)	Dr Bob Phillips (BP)
Dr Peter Jenkins (PJ)	Dr Anne Davidson (AD)
Dr Barbara Crosse (BC)	Dr Anton Kruger (AK)
Ms Wendy King (WK)	Ms Anne Higgins (AH)
Ms Jeanette Hawkins (JH)	Ms Miranda Holmes (MH)
Ms Catherine Oakley (CO)	Dr Mark Holland (MHo)
Dr Paul Wallman (PW)	Dr Helen Clayson (HC)
Ms Janie Thomas (JT)	Dr Nicola Perry (NP)
NCC-C and affiliated staff	
Dr John Graham (JG)	Dr Andrew Champion (AC)
Lianne Black (LB)	Angela Bennett (AB)
Nathan Bromham (NB)	Sabine Berendse (SB)
Timothy Simmons (TS)	Bernadette Li (BL)
NICE staff	
Claire Turner (CT)	Barbara Meredith (BM)
In Attendance	
Karen Francis (KF)	Lily Huajie Jin (LHJ)

REPORT OF DISCUSSIONS AT THE MEETING

1. Introductions and declarations of interest

BH welcomed everyone to the 1st meeting of the Neutropenic Sepsis GDG and thanked the GDG members for volunteering for the group. Each member of the group introduced themselves and gave a background to where they are from and what they do.

2. Declarations of interest

Interests declared before the 1st GDG meeting:

- BH declared that he had received an honorarium from GlaxoSmithKline in July 2009 to lecture and advise in a meeting on renal cancer. This interest was categorised as personal pecuniary non-specific meaning that BH can participate in discussion of all guideline topics.
- BH declared that he was local principal investigator for GlaxoSmithKline renal cancer study up until July 2009. This interest was categorised as non-personal pecuniary non-specific meaning that BH can participate in discussion of all guideline topics.
- BH declared that he chaired co-educational meetings, supported by grants from Pfizer and Chugai on trophoblastic disease in November 2009. This interest was categorised as non-personal pecuniary non-specific meaning that BH can participate in discussion of all guideline topics.

- BP declared that he is presently a member of the Children's Cancer and Leukaemia Supportive Care Group (CCLG). This interest was categorised as personal non-pecuniary meaning that BP can participate in discussion of all guideline topics.
- BP declared that he undertook research funded by MRC to develop/refine risk stratification criteria for febrile neutropenia episodes in children/young people undergoing cancer treatment, from October 2008 until October 2013. This interest was categorised as non-personal pecuniary specific meaning that BP must withdraw from all topics that include risk stratification criteria in children/young people with cancer. However, BP can be asked specific technical questions about the topic.
- JH declared she currently has managerial responsibility for services providing care for patients with neutropenic sepsis. This interest was categorised as non-personal pecuniary specific meaning that JH can participate in discussion of all guideline topics.
- JH declared that she currently line manages delivery of the paediatric practical oncology programme: supportive care module (accredited by Birmingham City University). This interest was categorised as non-personal pecuniary specific meaning that JH can participate in discussion of all guideline topics.
- AK declared he attended the European Haematology Society meeting in June 2010. Travelling expenses and subsistence were reimbursed by Sandoz. This interest was categorised as personal pecuniary non-specific as reimbursement was not beyond reasonable amounts meaning that AK can participate in discussion of all guideline topics.
- AK declared that he may be receiving an honorarium from Novartis to discuss myelodysplastic and iron chelation therapy in September 2010. This interest was categorised as personal pecuniary non-specific meaning that AK can participate in discussion of all guideline topics.
- CO declared that she is presently a board member of the UK Oncology Nursing Society. This interest was categorised as personal non-pecuniary meaning that CO can participate in discussion of all guideline topics.
- PJ declared he received funding from Sanofi Aventis regarding a review written on TAC chemotherapy in breast cancer in May 2009. This interest was categorised as personal pecuniary non-specific meaning that PJ can participate in discussion of all guideline topics.

The following new interests were declared at the meeting.

- JH declared she currently hands out free digital thermometers, supplied by Chugai, at Birmingham Children's Hospital. This interest was categorised as non-personal pecuniary specific meaning that JH must withdraw from discussions on all topics that include the use of thermometers.
- PJ declared that he received an honorarium to lecture to pharmaceutical reps for Sanofi Aventis on the risk of febrile neutropenia with docetaxel based chemotherapy in the summer of 2009. This interest was categorised as personal pecuniary specific meaning that PJ must withdraw from discussion on all topics that include febrile neutropenia with doxetaxel. However subject area is not being investigated by the guideline.
- PJ declared that he received an honorarium from Astra-Zeneca to attend an advisory board for market research on the hormonal treatment Faslodex in December 2009. This interest was categorised as personal pecuniary non-specific meaning that PJ can participate in discussion of all guideline topics.
- PJ declared that he received a travel grant from Boehringer Ingelheim to present papers to the ECCO meeting in Berlin in September 2009. This interest was categorised as personal pecuniary non-specific as reimbursement was not beyond reasonable amounts meaning that PJ can participate in discussion of all guideline topics.

- PJ declared that he received a payment from Succinct Communications sponsored by Sanofi Aventis to write a short article on planned dose on time-implications for docetaxel (Taxotere) chemotherapy efficacy for Medical Matters magazine for Oncologists in September 2010. This interest was categorised as personal pecuniary non-specific meaning that PJ can participate in discussion of all guideline topics.
- MHo declared that he attended a meeting sponsored by Sanofi Aventis on a new anti-arrhythmic drug in September 2010. Dinner and accommodation were paid by Sanofi Aventis. This interest was categorised as personal pecuniary non-specific meaning that MHo can participate in discussion of all guideline topics.
- MHo declared that he appraised and wrote a report of the Christie Hospital Acute Medical Services in August 2010. The Christie paid the locum fees to cover MHo's clinical work. This interest was categorised as non-personal pecuniary non-specific meaning that MHo can participate in discussion of all guideline topics.
- MHo declared he works on the hospital chemotherapy group and North West acute cancer network. This interest was categorised as personal non-pecuniary meaning that MHo can participate in discussion of all guideline topics.

3. Discussion

The GDG were given an introduction to NICE and its guideline development methodology.

A presentation was given on the needs assessment, outlining what data could be collected and from where. The GDG suggested additional data that could be collected and possible sources of this data.

The GDG discussed the guideline scope and the topics that would be investigated. The group then drafted and agreed a PICO question for each topic.

The GDG identified those topics which were potential priorities for economic investigation.

4. Close of meeting

BH thanked the GDG for their input to the meeting, and reminded them that the next meeting would be on Wednesday 24 November 2010, starting at 10.45am in the Dee Room, NICE, Manchester and closed the meeting.